Andrzej Jakubowiak to Biomarkers, Tumor
This is a "connection" page, showing publications Andrzej Jakubowiak has written about Biomarkers, Tumor.
Connection Strength
0.127
-
Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy. Oncotarget. 2016 Aug 30; 7(35):56726-56736.
Score: 0.064
-
Prognostic Significance of Cell-Free DNA Derived 5-Hydroxymethylcytosine Signatures in Newly Diagnosed Multiple Myeloma. JCO Precis Oncol. 2026 Jul; 10(7):e2501121.
Score: 0.032
-
Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2017 09; 17(9):555-562.
Score: 0.017
-
Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma. Leuk Lymphoma. 2015; 56(10):2959-61.
Score: 0.015